Clinical trials with amphetamine-blocking drugs.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000661:Amphetamine / Q000037:antagonists & inhibitors; D002746:Chlorpromazine / Q000627:therapeutic use; D005059:Euphoria / Q000187:drug effects; D006801:Humans; D008781:Methyltyrosines / Q000627:therapeutic use*; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000188:drug therapy*; D013881:Thioridazine / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D008781:Methyltyrosines; D014149:Tranquilizing Agents; D010643:Phenoxybenzamine; D011433:Propranolol; D000661:Amphetamine; D013881:Thioridazine; D002746:Chlorpromazine